The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...
Thousands of lawsuits cite studies linking paraquat to Parkinson’s disease. The EPA says the evidence doesn't warrant a ban ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...